Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)

Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)

Abstract Background Oesophageal and gastrooesophageal junction (GOJ) carcinoma frequently present with dysphagia and de novo metastatic disease. There is scope to improve treatment paradigms to both address symptoms and improve survival. One method is integrating immune checkpoint inhibition with no...

Full description

Bibliographic Details
Main Authors: Fiona Day, Swetha Sridharan, James Lynam, Craig Gedye, Catherine Johnson, Allison Fraser, Stephen R. Thompson, Michael Michael, Trevor Leong, Amitesh Roy, Mahesh Kumar, Andre van der Westhuizen, Gaik T. Quah, Hiren Mandaliya, Girish Mallesara, Joshua Sappiatzer, Christopher Oldmeadow, Jarad Martin
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Cancer
Subjects:
Oesophageal
Gastro-oesophageal (GOS)
Dysphagia
Oligometastatic
Chemoradiotherapy
Checkpoint inhibition
Online Access:https://doi.org/10.1186/s12885-022-10407-8

Internet

https://doi.org/10.1186/s12885-022-10407-8

Similar Items